Highly-expressed P2X7 Receptor Promotes Growth and Metastasis of Human HOS/MNNG Osteosarcoma Cells Via PI3K/Akt/GSK3β/β-catenin and MTOR/HIF1α/VEGF Signaling

Overview

Journal Int J Cancer

Specialty Oncology

Date 2019 Feb 15

PMID 30761524

Citations 79

Authors

Yingchi Zhang

Hao Cheng

Wenkai Li

Hua Wu

Yong Yang

Affiliations

Soon will be listed here.

Abstract

The P2X7 receptor, an ATP-gated ion channel, is critical for cancer cell growth, invasiveness, and angiogenesis. Previous studies indicate that P2X7 regulates osteoblast proliferation and osteodeposition and that high P2X7 expression has a pro-growth effect in osteosarcoma. However, how it functions in osteosarcoma cell growth and metastasis is not clear. Thus, we elucidated molecular mechanisms of P2X7-dependent positive regulation of osteosarcoma cell proliferation, invasion, migration, epithelial to mesenchymal transition (EMT), and angiogenesis using in vitro and in vivo models. We confirm that P2X7 is highly-expressed in human osteosarcoma tumor tissues and HOS/MNNG, MG63, U2OS, SW1353 and SAOS-2 cell lines. P2X7 receptor stimulation enhanced HOS/MNNG and SAOS-2 cell proliferation, migration and invasion; but knockdown of P2X7 expression or receptor inhibition had opposite effects. P2X7 positively regulated glycogen content, epithelial to mesenchymal transition and stemness of HOS/MNNG cells. P2X7 activation promoted PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling, thereby mediating pro-tumor effects of osteosarcoma cells. Consistent with data from in vitro experiments, systemic administration of P2X7 agonist induced tumor growth, metastasis and tumor-associated bone destruction in osteosarcoma-bearing nude mice, whereas a P2X7 antagonist reversed these effects. Thus, the P2X7 receptor participates in regulation of osteosarcoma growth and metastasis and we offer evidence that P2X7 may be a promising therapeutic target for treating osteosarcoma.

Citing Articles

5-hydroxymethylcytosine features of portal venous blood predict metachronous liver metastases of colorectal cancer and reveal phosphodiesterase 4 as a therapeutic target.

Xu N, Gao Z, Wu D, Chen H, Zhang Z, Zhang L Clin Transl Med. 2025; 15(2):e70189.

PMID: 39956959 PMC: 11830572. DOI: 10.1002/ctm2.70189.

Transcriptome Analysis Suggests PKD3 Regulates Proliferative Glucose Metabolism, Calcium Homeostasis and Microtubule Dynamics After MEF Spontaneous Immortalization.

Loaiza-Moss J, Braun U, Leitges M Int J Mol Sci. 2025; 26(2).

PMID: 39859313 PMC: 11765705. DOI: 10.3390/ijms26020596.

The Role of Adenosine in Overcoming Resistance in Sarcomas.

Cruz-Ramos M, Cabrera-Nieto S, Murguia-Perez M, Fajardo-Espinoza F Int J Mol Sci. 2024; 25(22).

PMID: 39596278 PMC: 11594806. DOI: 10.3390/ijms252212209.

Li M, Long S, Liu W, Long K, Gao X Front Pharmacol. 2024; 15:1419040.

PMID: 39170698 PMC: 11335561. DOI: 10.3389/fphar.2024.1419040.

Antifibrotic effect of the P2X7 receptor antagonist A740003 against acute myocardial infarction-induced fibrotic remodelling.

Almusallam N, Alonazi A, Bin Dayel A, Almubarak A, Ali R, Althakfi W Saudi Pharm J. 2024; 32(7):102102.

PMID: 39035363 PMC: 11258548. DOI: 10.1016/j.jsps.2024.102102.

References

Alqallaf S, Evans B, Kidd E . Atypical P2X receptor pharmacology in two human osteoblast-like cell lines. Br J Pharmacol. 2009; 156(7):1124-35. PMC: 2697685. DOI: 10.1111/j.1476-5381.2009.00119.x. View

Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F . Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One. 2008; 3(7):e2599. PMC: 2440522. DOI: 10.1371/journal.pone.0002599. View

Chen Q, Jiao D, Wu Y, Chen J, Wang J, Tang X . MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway. Oncotarget. 2016; 7(14):18247-61. PMC: 4951285. DOI: 10.18632/oncotarget.7570. View

Zubair H, Azim S, Srivastava S, Ahmad A, Bhardwaj A, Khan M . Glucose Metabolism Reprogrammed by Overexpression of IKKε Promotes Pancreatic Tumor Growth. Cancer Res. 2016; 76(24):7254-7264. PMC: 5161695. DOI: 10.1158/0008-5472.CAN-16-1666. View

Giannuzzo A, Pedersen S, Novak I . The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol Cancer. 2015; 14:203. PMC: 4660609. DOI: 10.1186/s12943-015-0472-4. View

Jelassi B, Chantome A, Alcaraz-Perez F, Baroja-Mazo A, Cayuela M, Pelegrin P . P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene. 2011; 30(18):2108-22. DOI: 10.1038/onc.2010.593. View

Baricordi O, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G . Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem. 1999; 274(47):33206-8. DOI: 10.1074/jbc.274.47.33206. View

Amoroso F, Falzoni S, Adinolfi E, Ferrari D, Di Virgilio F . The P2X7 receptor is a key modulator of aerobic glycolysis. Cell Death Dis. 2012; 3:e370. PMC: 3434661. DOI: 10.1038/cddis.2012.105. View

Roseweir A, Kong C, Park J, Bennett L, Powell A, Quinn J . A novel tumor-based epithelial-to-mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer. Int J Cancer. 2018; 144(1):150-159. DOI: 10.1002/ijc.31739. View

10.

Zhou B, Deng J, Xia W, Xu J, Li Y, Gunduz M . Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004; 6(10):931-40. DOI: 10.1038/ncb1173. View

11.

Link M, Goorin A, Miser A, Green A, Pratt C, Belasco J . The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314(25):1600-6. DOI: 10.1056/NEJM198606193142502. View

12.

Cheng K, Agarwal R, Mitra S, Lee J, Carey M, Gray J . Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med. 2012; 4(2):125-41. PMC: 3306554. DOI: 10.1002/emmm.201100193. View

13.

Shen Y, Zhang W, Liu J, He J, Cao R, Chen X . Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET. Int J Cancer. 2018; 144(3):651-664. DOI: 10.1002/ijc.31915. View

14.

Di Virgilio F . Purines, purinergic receptors, and cancer. Cancer Res. 2012; 72(21):5441-7. DOI: 10.1158/0008-5472.CAN-12-1600. View

15.

Giuliani A, Colognesi D, Ricco T, Roncato C, Capece M, Amoroso F . Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma. PLoS One. 2014; 9(9):e107224. PMC: 4165768. DOI: 10.1371/journal.pone.0107224. View

16.

Burnstock G, Di Virgilio F . Purinergic signalling and cancer. Purinergic Signal. 2013; 9(4):491-540. PMC: 3889385. DOI: 10.1007/s11302-013-9372-5. View

17.

Di Virgilio F, Adinolfi E . Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2016; 36(3):293-303. PMC: 5269532. DOI: 10.1038/onc.2016.206. View

18.

Oh E, Kim Y, An H, Sung D, Cho T, Farrand L . Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. Int J Cancer. 2018; 143(8):1978-1993. DOI: 10.1002/ijc.31585. View

19.

Adinolfi E, Callegari M, Ferrari D, Bolognesi C, Minelli M, Wieckowski M . Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005; 16(7):3260-72. PMC: 1165409. DOI: 10.1091/mbc.e04-11-1025. View

20.

Favaro E, Bensaad K, Chong M, Tennant D, Ferguson D, Snell C . Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab. 2012; 16(6):751-64. DOI: 10.1016/j.cmet.2012.10.017. View